Arctigenin Inhibits Lung Metastasis of Colorectal Cancer by Regulating Cell Viability and Metastatic Phenotypes

• Main Authors: Yo-Han Han, Ji-Ye Kee, Dae-Seung Kim, Jeong-geon Mun, Mi-Young Jeong, Sang-Hyun Park, Byung-Min Choi, Sung-Joo Park, Hyun-Jung Kim, Jae-Young Um, Seung-Heon Hong
• Format: Article
• Language: English
• Published: MDPI AG 2016-08-01
• Series: Molecules
• Subjects: Arctigenin; colorectal cancer; apoptosis; lung metastasis
• Online Access: http://www.mdpi.com/1420-3049/21/9/1135

Arctigenin (ARC) has been shown to have an anti-cancer effect in various cell types and tissues. However, there have been no studies concerning metastatic colorectal cancer (CRC). In this study, we investigated the anti-metastatic properties of ARC on colorectal metastasis and present a potential candidate drug. ARC induced cell cycle arrest and apoptosis in CT26 cells through the intrinsic apoptotic pathway via MAPKs signaling. In several metastatic phenotypes, ARC controlled epithelial-mesenchymal transition (EMT) through increasing the expression of epithelial marker E-cadherin and decreasing the expressions of mesenchymal markers; N-cadherin, vimentin, β-catenin, and Snail. Moreover, ARC inhibited migration and invasion through reducing of matrix metalloproteinase-2 (MMP-2) and MMP-9 expressions. In an experimental metastasis model, ARC significantly inhibited lung metastasis of CT26 cells. Taken together, our study demonstrates the inhibitory effects of ARC on colorectal metastasis.